Skip navigation

DAY ONE | Thursday, November 30, 2017

DIXIE BRANDS INTERACTIVE SITE TOUR!

7:00am

Pre-Tour Continental Breakfast

8:00am – 10:30am

This optional, interactive site tour presented by Leafly will give our cannabis industry attendees a chance to visit Dixie Brands manufacturing center to meet with the Director of Science Jay Denniston. Hear from an industry leader in Cannabis-based products how products are designed for a number of delivery mechanisms spanning Oral Mucosal, Ingestion, Inhalation, and Topical. This tour will give you a chance to learn more about leading manufacturing processes, regulations, and best practices in patient/consumer education and transparency.

10:30

Conference Registration and Refreshments

11:00

Chairman’s Welcome and Opening Remarks

Jeffrey Raber
Executive Director
Association of Commercial Cannabis Laboratories (ACCL)

Product Development of Cannabis-Based Medications and Therapies

11:15

Managing and Mitigating Oncology Side Effects with Cannabis-Based Therapies

Guy Chamberland
Chief Scientific Officer
Tetra Biopharma

12:00

Networking Luncheon

1:00

Source Management —
Identifying, Measuring and Standardizing Control of Pesticides and Adulterants

Jeffrey Raber
Executive Director
Association of Commercial Cannabis Laboratories (ACCL)

1:45

Epidermolysis Bullosa (EB) to Glaucoma —
Identifying Pathology Candidates for Cannabis-Based Treatments

Sazzad Hossain
Founder & Chief Scientific Officer
InMed Pharmaceuticals

2:30

Networking and Refreshment Break

Mastering Clinical Trials for Emerging Cannabis Therapies

3:00

Key Concerns in Setting Up, Managing and Executing Clinical Trials for Cannabis-Based Therapies

Graham Wood
Executive Vice President, Phase I Clinical Development
Altasciences Clinical Research

3:45

Establishing Scientific Standards in Clinical Trials for Cannabis Therapies

Paul Lyons
Medical Director
Virginia Comprehensive Epilepsy Program

4:30

Evaluating the Abuse Potential of Cannabinoids —
Challenges in an Evolving Regulatory Climate

Beatrice Setnik, PhD
VP, Scientific & Medical Affairs – Early Phase
INC Research / inVentiv Health

5:15

Production of Pharmaceutical Grade Cannabinoids by Means of Biocatalysis and Synthetic Biology

Richard Peet, JD, PhD
Executive Vice President, Chief Intellectual Property Counsel
Teewinot Life Sciences Corporation

6:00

Chairman’s Closing Remarks

Networking, Wine and Cheese Reception immediately following the final session on day one

DAY TWO | Friday, December 1, 2017

7:30

Continental Breakfast

8:45

Chairman’s Welcome and Review of Day One

Jeffrey Raber
Executive Director
Association of Commercial Cannabis Laboratories (ACCL)

Regulatory Updates and Navigating the Legal Landscape

9:00

Establishing and Promoting Adoption of Industry Quality Standards

Lezli Engelking
Executive Director
Foundation of Cannabis Unified Standards (FOCUS)

9:45

Networking and Refreshment Break

10:30

Northeast Medical Cannabis Perspective —
An Alternative View of the Universe and its Application

Tom Schultz
President
Connecticut Pharmaceutical Solutions

Rino Ferrarese
Chief Operating Officer
Connecticut Pharmaceutical Solutions

11:15

The Future of Cannabis Medicine — An Unfolding Political and Scientific Landscape

Bob Hoban
Director
Hoban Law Group

Michael Chernis
Founder
Chernis Law Group P.C.

Patient Profiles, Promising Therapies and the Role of Advocacy

12:00

Networking Luncheon

1:00

The Role of Cannabis in Combating Veteran’s Health Issues —
From PTSD to Chronic Pain

Nick Etten
Executive Director
Veteran’s Cannabis Project

1:45

Neurodegenerative Disorders and the Endocannabinoid System —
The Current State of Research Pathways

Mikhail Kogan, MD
Medical Director, GW Center for Integrative Medicine,
Assistant Professor of Medicine, Associate Director of Geriatric Fellowship
George Washington University

2:30

Can Big Pharma and Artisanal Cannabis Medicine Co-Exist?

Martin A. Lee
Co-Founder & Director
Project CBD

Adrian Devitt-Lee
Senior Research Associate, CannaCraft, Inc.;
Contributing Writer, Project CBD

3:15

Networking and Refreshment Break

3:30

Neuroprotective and Anti-Inflammatory Effects of KLS-13109 and Cannabidiol

Bill Kinney
President
IntraMed

4:15

Collaborating Across Industry to Make the Case for the Role of Cannabis as an Ingredient and Medication in Modern Medicine

Brian J. Fisher
Vice President of Operations & Corporate Partnerships
The Sturge Weber Foundation

5:00

CLOSING KEYNOTE The Future of Innovation for Cannabis Therapies from R&D to Product Launch and the Road Ahead

Marc Wayne
Founding President & Director
Canopy Health Innovations

5:45

Chairman’s Closing Remarks and End of Conference

Want more agenda details? Download the brochure.

DAY ONE | Thursday, November 30, 2017

DIXIE BRANDS INTERACTIVE SITE TOUR!

7:00am

Pre-Tour Continental Breakfast

8:00am – 10:30am

This optional, interactive site tour presented by Leafly will give our cannabis industry attendees a chance to visit Dixie Brands manufacturing center to meet with the Director of Science Jay Denniston. Hear from an industry leader in Cannabis-based products how products are designed for a number of delivery mechanisms spanning Oral Mucosal, Ingestion, Inhalation, and Topical. This tour will give you a chance to learn more about leading manufacturing processes, regulations, and best practices in patient/consumer education and transparency.

10:30

Conference Registration and Refreshments

11:00

Chairman’s Welcome and Opening Remarks

Jeffrey Raber
Executive Director
Association of Commercial Cannabis Laboratories (ACCL)

Product Development of Cannabis-Based Medications and Therapies

11:15

Managing and Mitigating Oncology Side Effects with Cannabis-Based Therapies

Guy Chamberland
Chief Scientific Officer
Tetra Biopharma

12:00

Networking Luncheon

1:00

Source Management —
Identifying, Measuring and Standardizing Control of Pesticides and Adulterants

Jeffrey Raber
Executive Director
Association of Commercial Cannabis Laboratories (ACCL)

1:45

Epidermolysis Bullosa (EB) to Glaucoma —
Identifying Pathology Candidates for Cannabis-Based Treatments

Sazzad Hossain
Founder & Chief Scientific Officer
InMed Pharmaceuticals

2:30

Networking and Refreshment Break

Mastering Clinical Trials for Emerging Cannabis Therapies

3:00

Key Concerns in Setting Up, Managing and Executing Clinical Trials for Cannabis-Based Therapies

Graham Wood
Executive Vice President, Phase I Clinical Development
Altasciences Clinical Research

3:45

Establishing Scientific Standards in Clinical Trials for Cannabis Therapies

Paul Lyons
Medical Director
Virginia Comprehensive Epilepsy Program

4:30

Evaluating the Abuse Potential of Cannabinoids —
Challenges in an Evolving Regulatory Climate

Beatrice Setnik, PhD
VP, Scientific & Medical Affairs – Early Phase
INC Research / inVentiv Health

5:15

Production of Pharmaceutical Grade Cannabinoids by Means of Biocatalysis and Synthetic Biology

Richard Peet, JD, PhD
Executive Vice President, Chief Intellectual Property Counsel
Teewinot Life Sciences Corporation

6:00

Chairman’s Closing Remarks

Networking, Wine and Cheese Reception immediately following the final session on day one

DAY TWO | Friday, December 1, 2017

7:30

Continental Breakfast

8:45

Chairman’s Welcome and Review of Day One

Jeffrey Raber
Executive Director
Association of Commercial Cannabis Laboratories (ACCL)

Regulatory Updates and Navigating the Legal Landscape

9:00

Establishing and Promoting Adoption of Industry Quality Standards

Lezli Engelking
Executive Director
Foundation of Cannabis Unified Standards (FOCUS)

9:45

Networking and Refreshment Break

10:30

Northeast Medical Cannabis Perspective —
An Alternative View of the Universe and its Application

Tom Schultz
President
Connecticut Pharmaceutical Solutions

Rino Ferrarese
Chief Operating Officer
Connecticut Pharmaceutical Solutions

11:15

The Future of Cannabis Medicine — An Unfolding Political and Scientific Landscape

Bob Hoban
Director
Hoban Law Group

Michael Chernis
Founder
Chernis Law Group P.C.

Patient Profiles, Promising Therapies and the Role of Advocacy

12:00

Networking Luncheon

1:00

The Role of Cannabis in Combating Veteran’s Health Issues —
From PTSD to Chronic Pain

Nick Etten
Executive Director
Veteran’s Cannabis Project

1:45

Neurodegenerative Disorders and the Endocannabinoid System —
The Current State of Research Pathways

Mikhail Kogan, MD
Medical Director, GW Center for Integrative Medicine,
Assistant Professor of Medicine, Associate Director of Geriatric Fellowship
George Washington University

2:30

Can Big Pharma and Artisanal Cannabis Medicine Co-Exist?

Martin A. Lee
Co-Founder & Director
Project CBD

Adrian Devitt-Lee
Senior Research Associate, CannaCraft, Inc.;
Contributing Writer, Project CBD

3:15

Networking and Refreshment Break

3:30

Neuroprotective and Anti-Inflammatory Effects of KLS-13109 and Cannabidiol

Bill Kinney
President
IntraMed

4:15

Collaborating Across Industry to Make the Case for the Role of Cannabis as an Ingredient and Medication in Modern Medicine

Brian J. Fisher
Vice President of Operations & Corporate Partnerships
The Sturge Weber Foundation

5:00

CLOSING KEYNOTE The Future of Innovation for Cannabis Therapies from R&D to Product Launch and the Road Ahead

Marc Wayne
Founding President & Director
Canopy Health Innovations

5:45

Chairman’s Closing Remarks and End of Conference